Flagship Biosciences continues to expand its leadership position in pathology-focused tissue image analysis with the addition of Dr. Dan Rudmann as Vice President of Program Development.
Dr. Rudmann comes to Flagship with more than 18 years of experience in drug development and pathology, most recently as Global Head of Pathology at AstraZeneca. As Vice President of Program Development, Dr. Rudmann will play a pivotal role in the management of client drug development programs with an emphasis on operational planning and strategic initiatives.
“Dr. Rudmann brings a wealth of knowledge and experience to Flagship Biosciences. In his new role overseeing all program development, Dr. Rudmann’s management expertise will further engage Flagship in our client’s drug development processes by expanding our peer-to-peer interactions.” said Trevor Johnson, Flagship’s Chief Operating Officer. “By understanding the expectations that pharmaceutical companies’ have of their service providers, he will help further align Flagship’s deliverables with pharma strategic priorities.”
Flagship Biosciences, the industry leader in tissue image analysis, advances personalized medicine by quantifying and simplifying complex pathology. The company’s comprehensive “fit for purpose” image analysis platform transforms conventional, subjective methods of histopathology with clear actionable data to speed global drug development and approval.
“I am very excited to become part of the growing team at Flagship Biosciences. Collaborating closely with clients on their drug development programs using the advanced pathology image analysis technologies that Flagship is developing is an excellent opportunity,” said Dr. Rudmann. “I look forward to working with Flagship’s diverse team of pathologists, biologists, biostatisticians, and image analysis experts to deliver unique and innovative client tissue analysis solutions.”